Low doses of indinavir boosted with ritonavir in HIV infected Thai patients: Pharmacokinetics, efficacy and tolerability

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 6, 2005, Pages 1041-1044

  Cressey, Tim R ^a,b,f   Leenasirimakul, Prattana ^c   Jourdain, Gonzague ^a,b   Tod, Michel ^d   Sukrakanchana, Pra Ornsuda ^b   Kunkeaw, Suparat ^b   Puttimit, Chutima ^b   Lallemant, Marc ^a,e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b IRD 054 Program for HIV Prevention and Treatment   (Thailand)

^c Nakornping Provincial Hospital   (Thailand)

^d Assistance Publique Hôpitaux de Paris ^*  (France)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^f NONE   (Thailand)

Author keywords

HAART; Highly active antiretroviral therapy; HIV; Pharmacology; Thailand

Indexed keywords

INDINAVIR; LAMIVUDINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADULT; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FEMALE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MALE; NAUSEA; PRACTICE GUIDELINE; SKIN DISEASE; STEADY STATE; THAILAND; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; MALE; RITONAVIR; RNA, VIRAL;

EID: 21244495659     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki143     Document Type: Article

References (12)

1. National Guidelines for the Clinical Management of HIV Infection in Children and Adults. AIDS Division, Department of Communicable Disease Control. Ministry of Public Health, Nonthaburi Thailand.
2. van Leth F, Phanuphak P, Ruxrungtham K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253-63.
3. Kappelhoff BS, van Leth F, MacGregor TR et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10: 145-55.
4. Boyd M, Duncombe C, Ruxrungtham K et al. Indinavir TID vs indinavir/ritonavir BID in combination with AZT/3TC for HIV infection in nucleoside pretreated patients: HIV-NAT 005 76-week follow up. In: Programs and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 422-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
5. Burger D, Boyd M, Duncombe C et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother 2003; 51: 1231-8.
6. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
7. Burger DM, Hoetelmans RM, Hugen PW et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3: 215-20.
8. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18: 825-34.
9. HIVpharmacology.com. Editorial Board for TDM Guidelines: Optimising TDM in HIV Clinical Care. A Practical Guide to Performing Therapeutic Drug Monitoring (TDM) for Antiretroviral Agents. Version 1.0 edn.
10. Burger DM, Siebers MC, Hugen PW et al. Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J Acquir Immune Defic Syndr 2002; 29: 101-2.
11. Ghosn J, Lamotte C, Ait-Mohand H et al. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients. AIDS 2003; 17: 209-14.
12. Duvivier C, Myrto A, Marcelin AG et al. Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals. Antivir Ther 2003; 8: 603-9.